SafiShahdaMD

Oncology • Indianapolis, IN

Gastrointestinal Cancer, Hematologic Oncology

Assistant Professor, Medicine, IN Univ Sch of Med

Join to view full profile

Dr. Shahda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shahda's full profile

Already have an account?

Office
535 Barnhill Dr
Rm 473
Indianapolis, IN 46202
Phone+1 317-274-5000

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2010 - 2013
Indiana University School of MedicineResidency, Internal Medicine, 2007 - 2010
Damascus University Faculty of MedicineClass of 2004

Certifications & Licensure

IN State Medical License 2011 - 2023

Awards, Honors, & Recognition

Danny Danielson Inaugural Innovative Translational Award Hoosier Oncology Group

Clinical Trials

A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 1
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1
A Phase II Study of Neoadjuvant FOLFIRINOX Start of enrollment: 2014 Jun 03
Completed
Phase 2
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Start of enrollment: 2015 Nov 05
Completed
Phase 1
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Start of enrollment: 2017 May 25
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

15 citations
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186
Cameron Herting, Matthew R. Farren, Yan Tong, Ziyue Liu, Bert H. O'Neil
Cancer Immunology, Immunotherapy. 2021-06-23
47 citations
Positive changes among patients with advanced colorectal cancer and their family caregivers: a qualitative analysis
Catherine E. Mosher, Rebecca N. Adams, Paul R. Helft, Bert H. O'Neil, Safi Shahda
Psychology & Health. 2017-01-02
33 citations
Examining the effect of peer helping in a coping skills intervention: a randomized controlled trial for advanced gastrointestinal cancer patients and their family care...
Catherine E. Mosher, Ekin Secinti, Shelley A. Johns, Bert H. O'Neil, Paul R. Helft
Quality of Life Research. 2018-02-01

Journal Articles

Phase I Study of EUS-Guided Photodynamic Therapy for Locally Advanced Pancreatic Cancer
John M Dewitt, Bert O'Neil, Amikar Sehdev, Safi Shahda, Gastrointestinal Endoscopy
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX
Olumide Gbolahan, Amikar Sehdev, Howard H Wu, Safi Shahda, Clinical Cancer Research

Lectures

A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
Prospective trial of preoperative FOLFIRINOX in patients with resectable pancreatic ductal adenocarcinoma (PDAC): Report of early endpoints.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

Two Months of Therapy: A Case of Pathologic Complete Response to Chemo-Immunotherapy in a Patient with Metastatic Colorectal CancerDecember 2017

Other Languages

Arabic